|Day Low/High||51.23 / 51.64|
|52 Wk Low/High||37.73 / 52.64|
Shares of Valeant Pharmaceuticals were higher Monday on news that the company named a new CFO.
Valeant's new CFO Paul Herendeen is a 'solid' performer and a welcome addition to the beleaguered company, says Jim Cramer
Cramer said investors should be cheering the reported arrival of CFO Paul Herendeen at Valeant.
Pfizer agrees to acquire Medivation while Citi puts Foot Locker and Under Armour on the back-to-school shopping list.
A potential blockbuster drug deal is reportedly in the works.
Zoetis Inc. (NYSE:ZTS) today announced that Glenn David, Senior Vice President of Finance Operations, has been named Executive Vice President and Chief Financial Officer (CFO), and will assume responsibility for the...
Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept.
TheStreet's Jim Cramer says the humanization of pets is a growing investment opportunity.
The humanization of pets has sent spending soaring, which has some pet-related stock seeing major benefits.
Zoetis Inc. (NYSE:ZTS) today announced that it has completed the purchase of Scandinavian Micro Biodevices, a pioneer in developing and manufacturing microfluidic "lab on a chip" diagnostic analyzers and tests for...
Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.
Cramer has seen enough in this earnings season to come to some conclusions on what's working and what isn't.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
UBS' Stephen Freedman and Mizuho's Steven Ricchiuto explained why investors should not be concerned about the recent downturn of the market on CNBC today.
Zoetis (ZTS) stock was trading higher pre-market as it boosted its outlook after reporting better-than-expected earnings and revenue for the second quarter.
Trade-Ideas LLC identified Zoetis (ZTS) as a pre-market leader candidate
Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2016 and increased its revenue and adjusted net income guidance for full year 2016.
Zoetis (ZTS) is expected to post 2016 second-quarter results before tomorrow's opening bell.
Earnings season is still in full swing and Cramer wants you to know which stocks he'll be watching and how to use his knowledge to be a better investor.
The Point72 chief buys a slice of ownership in a computer-driven startup fund and puts $250 million under management with them.
Cramer is faithful to pet care drug maker Zoetis and he prefers Danaher over its split-off sibling Fortive.
Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.
BMO Capital Markets downgrades the pharmaceutical giant ahead of Q2 earnings as pricing pressure mounts and other potential headwinds begin to emerge.
U.S. futures look to follow the rally by other world market as Nintendo shares soar.
Trade-Ideas LLC identified Zoetis (ZTS) as a momo momentum candidate
Despite some turmoil in Brazil's economy, the country has established itself as one of the fast-growing pet markets in the world. Here's why.
Buying a 93% stake in Vallée SA for $400 million will enable it to surpass Ourofino SA in the South American nation and enhance its chances of being first globally.